AEZS Adds Hollings Cancer Center To Multi-National Phase 3 Trial; MRNA And Mirna Amend License Agreement
November 21, 2014 at 03:18 AM EST
AEZS announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina. MRNA announced they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics.
